Skip to content
2000
Volume 21, Issue 3
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background: Status epilepticus (SE) is a serious neurological disease that manifests as prolonged seizures that last more than 5 minutes and between such episodes, patients do not regain consciousness. It can result in cognitive defects, brain damage, or even death. It is commonly known that one of the causes can be an inflammatory process, but here we will focus on inflammation as a result of new onset refractory status epilepticus and, related to this, new promising forms of SE treatment. Particular emphasis has been focused on new-onset refractory status epilepticus (NORSE). Methods: Based on public research databases, drugs with anti-inflammatory activity – commonly used in different spheres of medicine – have been reviewed as potentially treating status epilepticus. Results: There is seizable clinical research suggesting that drugs that decrease inflammatory processes might be effective in terminating status epilepticus. Conclusion: There is growing evidence showing that adding anti-inflammatory drugs to basic antiepileptic treatment enhances the efficiency of the therapeutic process, with special potential in NORSE cases.

Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X21666221117152249
2023-03-01
2024-12-12
Loading full text...

Full text loading...

/content/journals/cn/10.2174/1570159X21666221117152249
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test